1Loeffler J,Stevens DA. Antifungal drug resistance. Clin Infect Dis,2003,36 (Suppl 1):S31-S41.
2Greer ND. Voficonazole: the newest triazole antifungal agent. Proc(Bayl Univ Med Cent) ,2003,16:241-248.
3Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis,2004,38: 161-189.
4Boyd AE, Modi S, Howard S.I, et al. Adverse reactions to voriconazole. Clin Infect Dis,2004,39:1241-1244.
5Deresinski SC,Stevens DA. Caspofungin. Clin Infect Dis,2003,36:1445-1457.
6Pfaller MA, Boyken L, Hollis RJ, et al. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbio1,2005,43:5425-5427.
7Hope WW, Warn PA, Sharp A, et al. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. J Infect Dis,2005,192:673-680.
8Ostrosky-Zeichner L. Novel approaches to antifungal prophylaxis.Expert Opin Investig Drugs,2004,13:665-672.
